Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel

What Was Tested

Researchers studied Enclomiphene (non-peptide SERM) in this randomized controlled trial publication.

Their aim was to compare oral enclomiphene citrate as an alternative to topical testosterone.

Why It Was Studied

Clomiphene citrate is employed off-label in men who have low testosterone and for the restoration of sperm counts in men who have used exogenous testosterone.

Clomiphene is a mixture of two diastereoisomers: zuclomiphene and enclomiphene.

Who Took Part

The study group was 12 men.

PubMed indexes the participants as adults and middle-aged adults, men only.

How the Study Was Run

The design is described as randomized and open-label.

The men were allocated by chance, so the Enclomiphene (non-peptide SERM) group and the comparison group should start out alike.

Everyone knew when Enclomiphene (non-peptide SERM) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

What Was Measured

Clomiphene citrate is employed off-label in men who have low testosterone and for the restoration of sperm counts in men who have used exogenous testosterone.

The researchers evaluated enclomiphene citrate in men with secondary hypogonadism.

PubMed files the paper under topics including Administration, Cutaneous, Biomarkers, Enclomiphene, Estradiol, Follicle Stimulating Hormone, Human, Gels and Hormone Replacement Therapy.

What This Means in Plain Language

The paper is a randomized and open-label study of Enclomiphene (non-peptide SERM) in 12 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 13 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (The journal of sexual medicine), a journal based in Netherlands.

More context: the Enclomiphene (non-peptide SERM) compound page, all human trials.